Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)

OBJECTIVETo analyse the effectiveness and safety of rivaroxaban vs. standard treatment (ST) in the prevention of venous thromboembolism after hip or knee replacement in daily clinical practice in Spain.MATERIAL AND METHODA sub-analysis of the Spanish data in the XAMOS international observational stu...

Full description

Saved in:
Bibliographic Details
Published inRevista española de cirugía ortopédica y traumatología Vol. 60; no. 1; pp. 44 - 52
Main Authors Granero, J, Díaz de Rada, P, Lozano, L M, Martínez, J, Herrera, A
Format Journal Article
LanguageSpanish
Published 01.01.2016
Online AccessGet full text

Cover

Loading…
More Information
Summary:OBJECTIVETo analyse the effectiveness and safety of rivaroxaban vs. standard treatment (ST) in the prevention of venous thromboembolism after hip or knee replacement in daily clinical practice in Spain.MATERIAL AND METHODA sub-analysis of the Spanish data in the XAMOS international observational study that included patients>18 years who received 10mg o.d. rivaroxaban or ST.FOLLOW-UPup to 3 months after surgery.PRIMARY OUTCOMESincidence of symptomatic/asymptomatic thromboembolic events, bleeding, mortality, and other adverse events;SECONDARY OUTCOMESuse of health resources and satisfaction after hospital discharge.RESULTSOf the total 801 patients included, 410 received rivaroxaban and 391 ST (64.7% heparin, 24.0% fondaparinux, 11% dabigatran). The incidence of symptomatic thromboembolic events and major bleeding was similar in both groups (0.2% vs. 0.8% wit ST and 0.7% vs. 1.3% with ST [EMA criteria]/0.0% vs. 0.3% with ST [RECORD criteria]). The adverse events incidence associated with the drug was significantly higher rivaroxaban (overall: 4.4% vs. 0.8% with ST, P=.001; serious: 1.5% vs. 0.0% with ST, P=.03). The rivaroxaban used less health resources after discharge, and the majority considered the tolerability as «very good« and the treatment as «very comfortable».DISCUSSIONRivaroxaban is at least as effective as ST in the prevention of venous thromboembolism prevention in daily clinical practice, with a similar incidence of haemorrhages. It provides greater satisfaction/comfort, and less health resources after discharge. These results should be interpreted taking into account the limitations inherent in observational studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ISSN:1988-8856
DOI:10.1016/j.recot.2015.05.009